Immunovant heads into its May 29 earnings event with the positioning picture reversed from a week ago — options traders have rotated from aggressive call buying to measurable put demand, even as the stock has surged nearly 29% over the past week to $33.83.
The shift in options is the sharpest change since the previous notes. The put/call ratio has climbed to 0.31, more than two standard deviations above its 20-day average of 0.18 — a meaningful pivot from the call-dominated extreme recorded earlier this month when the PCR sat at 0.05. That reading was the lowest of the past year; the current one is now the highest in recent weeks. Investors who were chasing upside into weakness are now hedging into strength. Short interest, by contrast, has barely moved — bears hold 11.1% of the free float, down fractionally on the week after a modest 7% rise over the past month. Borrow remains frictionless at 0.41% annualised, and availability is loose at 421% of short interest, so there is no mechanical pressure on existing short positions.
Analyst activity has been unusually concentrated in the days since the stock's 30% one-day jump on May 20. Guggenheim raised its target from $44 to $62 while maintaining Buy. B of A Securities lifted its target from $32 to $43, also keeping Buy. Goldman Sachs remains at Neutral with a $32 target — now below the current price — signalling that at least one bellwether sees the rally as having run ahead of the fundamentals. Truist holds at Hold with a $30 target, also underwater. The bull case centres on IMVT-1402's 81% responder rate in treatment-resistant patients, a $994M cash runway, and registration discussions with the FDA planned for the second half of 2026. The bear case is simpler: the company burns cash, the Phase 2 randomised withdrawal data carries statistical risk, and the most recent quarter showed a loss-per-share that came in above expectations.
Insider activity reinforces the cautious read. The COO, an independent director, the CFO, and the CTO all sold shares in April and May — modest in absolute dollar terms but consistent in direction. No insider has bought into the rally. Roivant Sciences, which controls 55% of the shares, has not changed its position. Among correlated peers, ROIV is up 2% on the week while VCYT has gained 17% — biotech sentiment broadly supportive, but not uniformly so.
The May 29 print is therefore less a test of whether IMVT-1402 works and more a test of whether management can frame a credible path to registration that justifies a stock trading 30% above where it was seven days ago.
See the live data behind this article on ORTEX.
Open IMVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
